Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California San Francisco, San Francisco, CA, USA.
Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Curr Allergy Asthma Rep. 2018 Feb 21;18(2):12. doi: 10.1007/s11882-018-0764-z.
The goal of this paper is to review the major adverse cutaneous reactions that have been reported to the most commonly used biologics.
Anti-TNF agents and immune checkpoint inhibitors have significant, immune-mediated cutaneous manifestations that can necessitate discontinuation. Anti-TNF agents, IL-6 inhibitors, and IL-12/23 inhibitors can paradoxically cause psoriasis flares or unmask previously undiagnosed psoriasis. IL-17 inhibitors are unique in increasing risk for Candida infections. Benign injection site reactions, non-specific rash, cellulitis, and hypersensitivity reactions are relatively common adverse events. A wide variety of cutaneous reactions caused by biologics have been reported, ranging from benign injection site reactions to life-threatening cutaneous reactions necessitating discontinuation of the implicated biologic agent.
本文旨在综述最常使用的生物制剂所报道的主要皮肤不良反应。
抗 TNF 制剂和免疫检查点抑制剂具有显著的免疫介导的皮肤表现，可能需要停药。抗 TNF 制剂、IL-6 抑制剂和 IL-12/23 抑制剂可能会反常地引起银屑病发作或揭示以前未诊断的银屑病。IL-17 抑制剂在增加真菌感染风险方面是独特的。良性注射部位反应、非特异性皮疹、蜂窝织炎和过敏反应是相对常见的不良事件。生物制剂引起的各种皮肤反应已有报道，从良性注射部位反应到危及生命的皮肤反应，需要停用相关的生物制剂。
